Results 1 to 10 of about 243 (91)

NEURoaid II (MLC901) in cognitively Impaired not demenTEd patientS (NEURITES): A pilot double blind, placebo‐controlled randomized trial [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2021
Objective To investigate the efficacy and safety of MLC901 in vascular cognitive impairment no dementia (VCIND) patients. Design This was a multi‐center, double‐blind, randomized, placebo‐controlled pilot study.
Christopher L. H. Chen, Trọng Hung Nguyen, Simeon Marasigan, Chun Fan Lee, Qingshu Lu, Nagaendran Kandiah, Deidre deSilva, Eddie Chong, Narayanaswamy Venketasubramanian   +8 more
doaj   +6 more sources

NeuroAid II (MLC901) in Haemorrhagic Stroke [PDF]

Case Reports in Neurology, 2020
Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke.
Chai-Hoon Nowel Tan, David Choy, Narayanaswamy Venketasubramanian   +2 more
doaj   +6 more sources

Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol [PDF]

BMJ Open, 2022
Introduction Traumatic brain injury (TBI) is a leading cause of death in young adults globally and 90% of cases are mild TBI. Treatment to facilitate recovery after TBI is needed.
Marek Majdan, Valery Feigin, Pavel Pilipenko, Anna Andreevna Ivanova, Yulia Vadimovna Kotsiubinskaya, Vera Naumovna Grigoryeva, Alexey Yevgenievich Khrulev   +6 more
doaj   +6 more sources

Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD II) for Acute Ischemic Brain Injury in Animal Models [PDF]

Journal of Evidence-Based Integrative Medicine, 2021
Introduction. Moleac (MLC) 901 is a traditional Chinese medication approved by the Sino Food and Drug Administration in 2001 for treating stroke. This study aims to analyze the efficacy of MLC901 in animal stroke models after medial cerebral artery ...
I. G. M. Aswin R. Ranuh MD, Gadis Meinar Sari MD, PhD, Budi Utomo MD, PhD, Nur Setiawan Suroto MD, Asra Al Fauzi MD, PhD   +4 more
doaj   +7 more sources

A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury. [PDF]

PLoS ONE
IntroductionAbout half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. Although up to 40% of adults with mild TBI experience persistent functional deficits, there is
Pavel I Pilipenko, Anna A Ivanova, Yulia V Kotsiubinskaya, Vera N Grigoryeva, Alexey Y Khrulev, Anatoly V Skorokhodov, Maxim M Gavrik, Nona N Mkrtchan, Marek Majdan, Peter Valkovic, Daria Rabarova, Suzanne Barker-Collo, Kelly Jones, Valery L Feigin   +13 more
doaj   +5 more sources

NeuroAiD^TM-II (MLC901) Promoted Neurogenesis by Activating the PI3K/AKT/GSK-3β Signaling Pathway in Rat Spinal Cord Injury Models [PDF]

Biomedicines
Traumatic damage to the spinal cord (SCI) frequently leads to irreversible neurological deficits, which may be related to apoptotic neurodegeneration in nerve tissue. The MLC901 treatment possesses neuroprotective and neuroregenerative activity.
Anam Anjum, Muhammad Dain Yazid, Muhammad Fauzi Daud, Jalilah Idris, Angela Min Hwei Ng, Amaramalar Selvi Naicker, Ohnmar Htwe Rashidah Ismail, Ramesh Kumar Athi Kumar, Yogeswaran Lokanathan   +8 more
doaj   +5 more sources

Inhibitory effect of MLC901 on axonal demyelination in experimental animals undergoing circumferential lumbal stenosis by increasing transforming growth factor-β1 levels [PDF]

Asian Spine Journal
Study Design Experimental study using circumferential lumbar stenosis (CLS) rat model. Purpose To investigate the effect of MLC901 administration on transforming growth factor (TGF)-β1 level and the degree of axonal demyelination in the CLS rat model ...
Kevin Jonathan Sjukur, Willy Adhimarta, Andi Asadul Islam, Bambang Priyanto, Andriany Qanitha   +4 more
doaj   +5 more sources

The Alzheimer's disease THErapy with NEuroaid (ATHENE) study protocol: Assessing the safety and efficacy of Neuroaid II (MLC901) in patients with mild‐to‐moderate Alzheimer's disease stable on cholinesterase inhibitors or memantine—A randomized, double‐blind, placebo‐controlled trial [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2019
Background Dementia is a large and growing health care burden globally, and its major cause is Alzheimer's disease (AD). MLC901 (Neuroaid II) is a simplified form of MLC601 (Neuroaid), a Traditional Chinese Medicine with neuroprotective and ...
Christopher L.H. Chen, Purabi Reang Sharma, Boon Yeow Tan, Casuarine Low, Narayanaswamy Venketasubramanian   +4 more
doaj   +4 more sources

Safety and Use of MLC601/MLC901 (NeuroAiD^TM) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry [PDF]

Brain Sciences, 2020
Background: MLC601/MLC901 (NeuroAiD™) is a combination of natural products shown to be safe and to aid neurological recovery after brain injuries, especially ischemic stroke. Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH)
Ramesh Kumar, Azizi Abu Bakar, Jegan Thanabalan, Sanmugarajah Paramasvaran, Charng Jeng Toh, Ainul Jaffar, Farizal Fadzil, Palaniandy Kamalanathan, Bee Hong Soon, Narayanaswamy Venketasubramanian   +9 more
doaj   +6 more sources

MLC901 (NeuroAiD II™) for cognition after traumatic brain injury: a pilot randomized clinical trial. [PDF]

Eur J Neurol, 2018
Treatments to facilitate recovery after traumatic brain injury (TBI) are urgently needed. We conducted a 9‐month pilot, randomized placebo‐controlled clinical trial to examine the safety and potential effects of the herbal supplement MLC901 (NeuroAiD II™)
Theadom A, Barker-Collo S, Jones KM, Parmar P, Bhattacharjee R, Feigin VL.   +5 more
europepmc   +6 more sources